Seclidemstat

Seclidemstat
Clinical data
Other namesSP-2577
Drug classLSD1 inhibitor
Identifiers
  • N-[(E)-1-(5-chloro-2-hydroxyphenyl)ethylideneamino]-3-(4-methylpiperazin-1-yl)sulfonylbenzamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC20H23ClN4O4S
Molar mass450.94 g·mol−1
3D model (JSmol)
  • C/C(=N\NC(=O)C1=CC(=CC=C1)S(=O)(=O)N2CCN(CC2)C)/C3=C(C=CC(=C3)Cl)O
  • InChI=InChI=1S/C20H23ClN4O4S/c1-14(18-13-16(21)6-7-19(18)26)22-23-20(27)15-4-3-5-17(12-15)30(28,29)25-10-8-24(2)9-11-25/h3-7,12-13,26H,8-11H2,1-2H3,(H,23,27)/b22-14+
  • Key:MVSQDUZRRVBYLA-HYARGMPZSA-N

Seclidemstat is an investigational new drug that is being evaluated for the treatment of cancer. It is a small-molecule inhibitor of lysine-specific demethylase 1 (LSD1, KDM1A).

References

  1. ↑ "Seclidemstat - Salarius Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
  2. ↑ Noce B, Di Bello E, Fioravanti R, Mai A (2023). "LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials". Frontiers in Pharmacology. 14 1120911. doi:10.3389/fphar.2023.1120911. PMC 9932783. PMID 36817147.